Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenic mechanisms for parathyroid hyperplasia.

A S Dusso1, T Sato, M V Arcidiacono

  • 1Renal Division, Washington University School of Medicine, St Louis, Missouri 63110, USA. adusso@im.wustl.edu

Kidney International. Supplement
|July 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerated atherosclerosis in ANCA-associated vasculitis.

Acta neurologica Scandinavica·2017
Same author

Leukoencephalopathy due to oral methotrexate.

Cerebellum (London, England)·2013
Same author

Neurological focal signs as a first manifestation of cardiac myxoma.

Neurologia (Barcelona, Spain)·2012
Same author

Crosstalk between chromatin structure, nuclear compartmentalization, and telomere biology.

Cytogenetic and genome research·2009
Same author

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Kidney international·2007
Same author

25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.

Kidney international·2006
Same journal

Effect of kidney disease on glucose handling (including genetic defects).

Kidney international. Supplement·2011
Same journal

Need for better diabetes treatment for improved renal outcome.

Kidney international. Supplement·2011
Same journal

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

Kidney international. Supplement·2011
Same journal

SGLT2 inhibitors: molecular design and potential differences in effect.

Kidney international. Supplement·2011
Same journal

Glucose handling by the kidney.

Kidney international. Supplement·2011
Same journal

Bone: from a reservoir of minerals to a regulator of energy metabolism.

Kidney international. Supplement·2011
See all related articles

Parathyroid hyperplasia in kidney disease is driven by transforming growth factor alpha (TGFα) and its receptor. Blocking this pathway with EGFR-tyrosine kinase inhibitors (TKI) prevents gland enlargement and vitamin D resistance.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Kidney disease (KD) causes parathyroid gland enlargement (hyperplasia) due to hypocalcemia, hyperphosphatemia, and vitamin D deficiency.
  • In the 5/6 nephrectomized rat model, KD-induced mitogenic signals in parathyroid cells are aggravated by high phosphate (P) or low calcium (Ca) diets.
  • Transforming growth factor alpha (TGFα) and its receptor, epidermal growth factor receptor (EGFR), are key drivers of parathyroid hyperplasia in experimental KD.

Purpose of the Study:

  • To investigate the role of TGFα/EGFR signaling in parathyroid hyperplasia associated with kidney disease.
  • To evaluate the efficacy of EGFR-tyrosine kinase inhibitors (TKI) in preventing and treating parathyroid hyperplasia in experimental KD.
  • To elucidate the mechanisms by which TGFα/EGFR signaling contributes to vitamin D resistance in secondary hyperparathyroidism.

Related Experiment Videos

Main Methods:

  • Utilized a 5/6 nephrectomized rat model to replicate features of human kidney disease.
  • Administered EGFR-tyrosine kinase inhibitors (TKI) to block TGFα-activated EGFR signaling.
  • Assessed parathyroid gland hyperplasia, TGFα and EGFR expression, and vitamin D receptor levels.

Main Results:

  • EGFR-TKI treatment completely prevented high P- and low Ca-induced parathyroid hyperplasia in early KD.
  • EGFR-TKI treatment halted the progression of high P-induced parathyroid growth in established secondary hyperparathyroidism.
  • TGFα self-upregulation is the primary determinant of hyperplastic growth severity, and its activation of EGFR reduces vitamin D receptor levels, causing calcitriol resistance.

Conclusions:

  • Targeting the TGFα/EGFR pathway with EGFR-TKI is a promising therapeutic strategy for parathyroid hyperplasia in kidney disease.
  • Inhibition of EGFR signaling can overcome vitamin D resistance in secondary hyperparathyroidism.
  • Understanding the TGFα/EGFR axis is crucial for managing parathyroid disorders in kidney disease patients.